Skip to main content

Table 1 Baseline and transplant characteristics of patients in Bu/Cy and t-IV Bu/Flu groups

From: Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

Variables Bu/Cy
(Freq/Percent)
Bu/Flu
(Freq/Percent)
Total
(Freq)
P-value
Name Level     
Time from diagnosis to HCT Months (median value, range) 6.2 (1-29) 6.4 (2-54)   0.5
Follow up time Months (median value, range) 8 (1-90) 17 (1-53)   0.245
Donor MRD 51
100.00
39
39.00
81 < .0001
  MUD 0
0.00
39
39.00
39  
  MMUD 0
0.00
22
22.00
22  
Cytogenetic Low 3
7.89
7
7.00
10 0.3568
  Intermediate 25
65.79
54
54.00
79  
  High 10
26.32
39
39.00
49  
ATG No 42
100.00
78
78.79
120 0.0006
  Yes 0
0.00
20
20.20
20  
Cell Source BM 35
68.63
2
2.00
37 < .0001
  PB 16
31.37
98
98.00
114  
aGVHD prophylaxis CSA/MTX 51
100.00
0
0.00
42 < .0001
  TAC/MMF 0
0.00
22
22.00
22  
  TAC/MTX 0
0.00
77
71.00
77  
  TAC/RAPA 0
0.00
1
1.00
1  
Disease Status CR1 19
37.25
49
49.00
68 0.0013
  CR2 or CR3 6
11.76
25
25.00
31  
  PIF 7
13.73
16
16.00
23  
  Relapse 18
35.29
9
9.00
27  
  UNT 1
1.96
1
1.00
2  
Diagnosis primary 41
80.39
62
62.00
103 0.0221
  secondary 10
19.61
38
38.00
48  
No of Induction 0 1
2.38
1
1.00
2 0.4882
  1 31
73.81
67
67.00
98  
  2 9
21.43
24
24.00
33  
  3 1
2.38
8
8.00
9  
AGE 39.0 (19.6-55.60) 48.16(21.84-68.64)   0.0001
WBC at Diagnosis 13.60 (0.80-190.00) 5.80 (0.25-285.00)   0.1073
Time in CR1 256 (12-762) 324.5 (21 - 2679)   0.1699
% Blast in BM 4 (0 - 88) 2 (0-80)   0.0028
Chimerism (day 90) BM 100 (55-100) 97 (10-100)   0.0925
  CD3 NA 90 (18-100)   NA
  CD33 NA 100 (10-100)   NA